XRN2

Across TCGA pan-cancer cohorts, XRN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated XRN2 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher XRN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated XRN2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SCLC, UCEC, and LUSC are the cancer types where XRN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.110	0.715	<.001	42	view →
UCEC	DFS	Median	All	0.787	0.632	.007	22	view →
LUSC	OS	Median	III,IV	0.086	0.684	<.001	12	view →
HNSC	OS	Median	IV	0.176	0.639	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

XRN2–SCLC (OS)

Open the SCLC breakdown →